Product
BRII-179
1 clinical trial
2 indications
Indication
Hepatitis BIndication
ChronicClinical trial
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) InfectionStatus: Completed, Estimated PCD: 2023-07-04